• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90.在一项低风险霍奇金淋巴瘤综合治疗试验中，疾病部位数量并无预后价值：重新审视PHC HOD90。
Blood Adv. 2023 Nov 14;7(21):6665-6667. doi: 10.1182/bloodadvances.2023010944.
2
[New treatment options for patients with Non-Hodgkin and Hodgkin lymphoma: changing treatment standards and improvements in prognosis].[非霍奇金淋巴瘤和霍奇金淋巴瘤患者的新治疗选择：治疗标准的改变与预后改善]
MMW Fortschr Med. 2023 Jan;165(1):48-51. doi: 10.1007/s15006-022-2185-0.
3
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.早期氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）评估联合临床风险评分可确定复发性淋巴瘤的预后。
Blood. 2007 Jan 15;109(2):486-91. doi: 10.1182/blood-2005-11-006957. Epub 2006 Sep 26.
4
The broader prospects for bispecifics in Hodgkin lymphoma.双特异性抗体在霍奇金淋巴瘤中的更广阔前景。
Leuk Lymphoma. 2022 Aug;63(8):1777-1779. doi: 10.1080/10428194.2022.2107205. Epub 2022 Aug 3.
5
Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors.接受化疗联合或不联合放疗治疗的霍奇金淋巴瘤的极晚期复发：线性模式及独特的预后因素
Blood Cancer J. 2022 Jul 5;12(7):102. doi: 10.1038/s41408-022-00674-w.
6
Adolescents with Hodgkin lymphoma: a great treatment challenge.患有霍奇金淋巴瘤的青少年：一项巨大的治疗挑战。
Lancet Haematol. 2022 Jan;9(1):e5-e6. doi: 10.1016/S2352-3026(21)00372-0.
7
[Hodgkin lymphoma and non-Hodgkin lymphoma].[霍奇金淋巴瘤和非霍奇金淋巴瘤]
Rinsho Ketsueki. 2013 Jan;54(1):81-8.
8
Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.经典型霍奇金淋巴瘤的生物学：对预后和新型治疗的影响。
Blood. 2018 Apr 12;131(15):1654-1665. doi: 10.1182/blood-2017-09-772632. Epub 2018 Mar 2.
9
[Composite lymphoma].[复合性淋巴瘤]
Med Clin (Barc). 2003 Sep 13;121(8):319. doi: 10.1016/s0025-7753(03)73935-9.
10
Bone marrow involvement by hodgkin and non-hodgkin lymphomas.霍奇金淋巴瘤和非霍奇金淋巴瘤的骨髓受累情况。
Hematol Oncol Clin North Am. 2009 Aug;23(4):873-902. doi: 10.1016/j.hoc.2009.04.014.

本文引用的文献

1
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.NCCN 指南®洞察：霍奇金淋巴瘤，第 2.2022 版。
J Natl Compr Canc Netw. 2022 Apr;20(4):322-334. doi: 10.6004/jnccn.2022.0021.
2
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.反应适应放疗省略与巩固化疗在中晚期经典霍奇金淋巴瘤患儿和青少年中的比较（欧洲血液与骨髓移植学会-儿童肿瘤组 Hodgkin 淋巴瘤协作组 1 期临床试验）：一项带有开放性标签、嵌入式、多国、非劣效、随机对照滴定研究。
Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 9.
3
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.早期霍奇金淋巴瘤中风险因素对结局的影响：对国际分期定义的分析。
Ann Oncol. 2013 Dec;24(12):3070-6. doi: 10.1093/annonc/mdt413. Epub 2013 Oct 22.
4
Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.儿童和青少年结节性淋巴细胞为主型霍奇金淋巴瘤——生物学、临床过程和治疗选择的全面综述。
Br J Haematol. 2012 Nov;159(3):288-98. doi: 10.1111/bjh.12055. Epub 2012 Sep 21.
5
Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.基于早期对 VAMP 化疗的反应，放疗与不放疗对儿童低危霍奇金淋巴瘤患者生存的影响。
JAMA. 2012 Jun 27;307(24):2609-16. doi: 10.1001/jama.2012.5847.
6
Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.采用VAMP方案及低剂量累及野放疗治疗低危霍奇金淋巴瘤患儿的前瞻性临床试验最终结果。
J Clin Oncol. 2007 Jan 20;25(3):332-7. doi: 10.1200/JCO.2006.08.4772.
7
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.临床I期或II期霍奇金淋巴瘤的综合治疗：欧洲癌症研究与治疗组织H7随机对照试验的长期结果
J Clin Oncol. 2006 Jul 1;24(19):3128-35. doi: 10.1200/JCO.2005.05.2746. Epub 2006 Jun 5.
8
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.对于早期预后不良的霍奇金淋巴瘤患者，在接受四个周期化疗后，受累野放疗与扩大野放疗疗效相当，但毒性更小：德国霍奇金淋巴瘤研究组HD8试验的结果
J Clin Oncol. 2003 Oct 1;21(19):3601-8. doi: 10.1200/JCO.2003.03.023. Epub 2003 Aug 11.

Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90.

作者信息

Feraco Angela M, Zhou Yiwang, Zheng Ying, Marks Lianna J, Friedmann Alison, Weinstein Howard J, Link Michael P, Flerlage Jamie E

机构信息

Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.

Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.

出版信息

Blood Adv. 2023 Nov 14;7(21):6665-6667. doi: 10.1182/bloodadvances.2023010944.

DOI:10.1182/bloodadvances.2023010944
PMID:37647596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10637876/
Abstract
摘要